Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

22-May-2007

Organon announced that it has now completed recruitment for both pivotal phase IIIa trials for NOMAC/E2, its novel oral contraceptive containing natural estrogen. According to the company, the success means the development program is on track for file submission in 2009.

NOMAC/E2 is the first monophasic oral contraceptive containing natural estrogen. It contains the estrogen estradiol (E2), which is similar to the one naturally present in the woman's body. All currently available combined oral contraceptives contain synthetic ethinyl-estradiol (EE), a chemically modified version of estrogen. The new combined pill also contains NOMAC (nomegestrol acetate), a hormone new in contraception, which resembles the progesterone a woman's body produces at certain times in her menstrual cycle.

The phase IIIa development program for NOMAC/E2 started in June 2006. The two large, randomized, open-label multi-centre, 13-cycle, comparative studies designed to evaluate the efficacy, cycle control, safety and acceptability of NOMAC/E2, will generate more than 30,000 cycles of exposure to NOMAC/E2. In total more than 180 centers in 24 countries including the USA, are taking part. Potential product pluses and non-contraceptive benefits specifically related to the use of this unique combination are under investigation in both trials. A number of smaller studies designed to assess the pharmacodynamic and metabolic aspects of NOMAC/E2 as required by the regulatory guidelines for development of a new contraceptive product are also underway.

Organon was granted development and marketing rights of NOMAC/E2 in 2005 by Laboratoire Théramex, an affiliate of Merck KGaA of Darmstadt, Germany. Théramex completed the phase II program indicating that NOMAC/E2 combines inhibition of ovulation with a stable bleeding pattern.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides

MedMira Reaches Funding Agreement to Enable US Market Expansion

Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies